Phase 1 Endometrial Cancer Trial, Recruiting NCT06544720 Sponsor: The Affiliated Hospital of Qingdao University Condition: Endometrial Cancer
Back to Endometrial Cancer

Phase 1 Endometrial Cancer Trial, Recruiting

NCT06544720
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are 18 years of age or older
  • People whose cancer is linked to HPV (Human Papillomavirus)
  • People who have at least one tumor or lesion that can be measured using standard imaging guidelines
  • People who are generally able to carry out normal daily activities with little or no limitation (this is measured using a standard scale called ECOG, with a score of 0 or 1)

Who may not be able to join:

  • People with active or uncontrolled infections, or serious ongoing illnesses affecting the heart or lungs
  • People with active autoimmune diseases (conditions where the immune system attacks the body's own tissues)
  • People with a known active Hepatitis B or Hepatitis C infection
  • People with other serious medical conditions that the trial site determines could limit safe participation in the trial

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +86 18661805217

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
The Affiliated Hospital of Qingdao University
Registry
ClinicalTrials.gov
Start date
2 August 2023
Est. completion
31 December 2025

Where this trial is recruiting

🇨🇳 China

Primary endpoints

DLT

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov